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OBJECTIVES The purpose of this study was twofold: 1) to examine the relationship between menstrual
cycle and coronary flow velocity reserve (CFVR) in young healthy women, and 2) to evaluate
the effect of hormone replacement therapy by estrogen on CFVR in postmenopausal women,
using transthoracic color Doppler echocardiography (TTCDE).
BACKGROUND Although the incidence of cardiovascular disease is lower in women before menopause
compared with men, postmenopausal women have an incidence of coronary artery disease
similar to that of men of the same age. This is mainly dependent upon estrogen deficiency.
However, no clinical report has yet examined the effect of estrogen on CFVR, which is one
index of coronary microcirculation.
METHODS We examined 15 male and both 15 premenopausal and 10 postmenopausal female healthy
volunteers. We measured coronary flow velocity of the left anterior descending coronary artery
at baseline and hyperemic conditions during adenosine triphosphate infusion by TTCDE and
determined CFVR. Each premenopausal woman was studied two times (menstrual [M] and
follicular [F] phases) in one menstrual cycle. Fifteen men were also studied at a time
corresponding to women’s menstrual cycle. The postmenopausal women were studied before
and two hours after oral administration of conjugated estrogen (CE).
RESULTS Serum 17-estradiol level in premenopausal women increased in the F phase and decreased
to the same levels as in men, as in the M phase and as in postmenopausal women (123 
9 pg/ml vs. 28  6 pg/ml, 25  9 pg/ml and 19  11 pg/ml; p  0.0001, respectively). The
CFVR increased in the F phase compared with that in the M phase (4.8  0.4 vs. 3.7  0.8,
p  0.0001). We found that CFVR in men remained unchanged (3.7  0.6 vs. 3.8  0.5).
After CE administration, CFVR increased compared with baseline in postmenopausal
women (4.1  0.8 vs. 3.4  0.8, p  0.005).
CONCLUSIONS In premenopausal women, CFVR determined by TTCDE varied during the menstrual cycle,
and in postmenopausal women, CFVR increased after acute estrogen replacement. (J Am
Coll Cardiol 2001;38:1879–84) © 2001 by the American College of Cardiology
The incidence of cardiovascular disease is lower in women
before menopause compared with men. Epidemiologic
studies and large randomized clinical trials consistently find
that hormone replacement therapy lowers the risk of coro-
nary heart disease in women (1–3). Estrogen may be
supposed to have a cardioprotective effect on women. In
addition, it has been reported that treatment with estrogen
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improves exercise time to myocardial ischemia in postmeno-
pausal women with proven coronary heart disease (4,5). A
recent report (6) shows that myocardial ischemia was more
easily induced in premenopausal women when estrogen
concentrations were low during the menstrual cycle. Fur-
thermore, variation in flow-mediated dilation of brachial
artery during the menstrual cycle has been reported in
human subjects (7). To the best of our knowledge, however,
no clinical report has examined the effect of estrogen on
coronary flow reserve, which is one index of coronary
microcirculation.
Recent development in transthoracic color Doppler echo-
cardiography (TTCDE) enables us to estimate coronary
flow reserve by measuring coronary flow velocity reserve
(CFVR) in vivo (8,9). Using this technique, the effect of
estrogen on coronary microcirculation may be investigated
noninvasively. The purpose of this study was to: 1) examine
the relationship between menstrual cycle and CFVR in
young, healthy women, and 2) using TTDE, evaluate the
effect of hormone replacement therapy by estrogen on
CFVR in postmenopausal women.
METHODS
Study population. A total of 15 male, and 17 premeno-
pausal and 11 postmenopausal female volunteers were en-
rolled in this study. The 15 male subjects, 24 to 37 years old,
were healthy medical doctors. The 17 premenopausal
women, 22 to 38 years old, were healthy nurses and doctors.
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They had regular menstrual cycles (26 to 36 days) for more
than three months before this study. None had a history of
pregnancy. The postmenopausal women, 56 to 76 years old,
were also healthy volunteers, all with plasma estradiol levels
50 pg/ml and cessation of menses for at least a year. All
subjects were asymptomatic, normotensive, nondiabetic and
nonsmokers. They had no significant medical history. No
subjects had taken any cholesterol-lowering agent, estrogen
therapy or antioxidant vitamin supplements for the preced-
ing two months. Each subject gave written informed con-
sent before the enrollment in this study after thorough
explanation of the study design and protocol.
Study design. Each premenopausal woman was studied
twice in one menstrual cycle. The measurement was done
once in the menstrual (M) phase and the follicular (F)
phase. To estimate their menstrual cycles, they checked
their body temperature every morning during this study.
Fifteen men were also studied twice (at the beginning of the
study and at two weeks), corresponding to women’s men-
strual phase, to evaluate the “cycle” effect. The postmeno-
pausal women were studied before and two hours after oral
administration of 1.25 mg of conjugated estrogen (CE).
Laboratory assays. Blood sampling was performed on the
morning of the ultrasound examination after a 14-h overnight
fasting (including caffeine) to measure serum concentrations of
17-estradiol, total cholesterol, triglycerides and high-density
lipoprotein (HDL) cholesterol. Serum 17-estradiol levels
were measured by radioimmunoassay. Blood (5 ml) was drawn
from the individuals immediately before each echocardio-
graphic study and was centrifuged at 1,000 g for 10 min.
Following centrifugation, serum was kept at80°C until assay.
Total cholesterol and triglycerides in the serum were quantified
by automated enzymatic techniques. Serum HDL cholesterol
was quantified after dextran sulfate precipitation of other
lipoproteins. All specimens were measured within 48 h after
the blood sampling.
Coronary flow studies. Echocardiography was performed
with the Acuson Sequoia 512 (Mountainview, California)
with a frequency of 7.0 MHz. In color Doppler flow
mapping, velocity range was set in the range of 12 cm/s.
The color gain was adjusted to provide the optimal images.
The ultrasound beam was transmitted toward the heart to
visualize coronary blood flow in the left anterior descending
coronary artery (LAD) by color Doppler echocardiography.
First, the left ventricle was imaged in the long-axis cross
section, and the ultrasound beam was inclined laterally.
Next, coronary blood flow in the distal portion of the LAD
was searched under the guidance of color Doppler flow
mapping. With a sample volume (2.5 or 3.0 mm wide)
positioned on the color signal in the LAD, Doppler spectral
tracings of flow velocity in the LAD were recorded by fast
Fourier transformation analysis. Although we tried to align
ultrasound beam direction to distal LAD flow as parallel as
possible, angle correction was needed in each examination
because of incident Doppler angle (mean angle 42°; range
31° to 58°).
We first recorded baseline spectral Doppler signals in the
distal portion of the LAD over five cardiac cycles at
end-expiration by TTDE. Intravenous adenosine triphos-
phate (ATP) was administered (140 g  kg1  min1 IV)
for 2 min to record spectral Doppler signals during hyper-
emic conditions. All subjects had a continuous heart rate
and electrocardiographic monitoring. Blood pressure was
recorded at baseline and every minute during ATP infusion.
Each study was analyzed by two experienced investigators
who were blinded to the other subject data. Measurements
were performed off-line by tracing the contour of the
spectral Doppler signal using the computer incorporated in
the ultrasound system. Mean diastolic velocities (MDVs)
were measured at baseline, and peak hyperemic conditions
were measured from the Doppler signal recordings.
Measurements were averaged over three cardiac cycles.
The CFVR was defined as the ratio of hyperemic to basal
MDV.
Statistical analysis. All the data were expressed as mean 
SD. Echocardiographic and hemodynamic variables during
ATP infusion in both pre- and postmenopausal women and
in men were evaluated by two-way repeated-measures anal-
ysis of variance (ANOVA), testing for estrogen effect, ATP
effect, and interaction. The Fisher protested least-significant
difference test was used for the post hoc test. The CFVR
values for M and F phases in premenopausal women, before
and after CE intake in postmenopausal women, and twice
in men were compared by paired t test. Laboratory data
were also analyzed by paired t test. For all analysis, p 0.05
was considered significant. Interobserver and intraobserver
variabilities were assessed for velocity measurement in 20
recordings in 10 randomly selected patients. Interobserver
variability was calculated as the SD of the differences
between the measurements of two independent observers
who were unaware of the other patient data, and this was
expressed as a percent of the average value. Intraobserver
variability was calculated as the SD of the differences
between the first and second determination (three-week
interval) for a single observer, and this was expressed as a
percent of the average value.
Abbreviations and Acronyms
ANOVA  analysis of variance
ATP  adenosine triphosphate
CE  conjugated estrogen
CFVR  coronary flow velocity reserve
F  follicular
HDL  high-density lipoprotein
LAD  left anterior descending coronary artery
LDL  low-density lipoprotein
M  menstrual
MDV  mean diastolic velocities
NO  nitric oxide
TTDE  transthoracic color Doppler echocardiography
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RESULTS
Under the guidance of color Doppler flow mapping, ade-
quate spectral Doppler recordings of coronary flow in the
distal portion of the LAD for the assessment of CFVR were
obtained in 40 (15 men, and 15 premenopausal and 10
postmenopausal women) of 43 study patients (93%). No
patient noted atrioventricular block, chest pain, flushing, or
palpitations during ATP infusion in the TTDE studies.
Table 1 shows the clinical characteristics of subjects, includ-
ing serum lipid profile and serum 17-estradiol level.
During drug administration, heart rate and systolic blood
pressure increased significantly (p  0.02, all groups).
Diastolic blood pressure decreased significantly (p  0.01,
all groups). However, the two-way ANOVA showed no
interaction in terms of heart rate, systolic blood pressure and
diastolic blood pressure between M and F phases, before
and after CE intake, and initial and follow-up at two weeks
in men during ATP infusion. There was no significant
difference of age between the men and the premenopausal
women groups.
Effects of gender, menstrual cycle and menopause on
serum 17-estradiol levels. Serum 17-estradiol levels of
premenopausal women were proved to be appropriate to
each menstrual phase with the consecutive estimation of
their previous menstrual cycles, morning body temperature
and actual menstruation during this study. Serum 17-
estradiol levels in premenopausal women increased in the F
phase. Serum 17-estradiol levels in men and in postmeno-
pausal women were also within normal ranges. In men,
serum 17-estradiol levels were measured twice a month at
a time corresponding to the women’s menstrual phase, and
serum hormone levels remained unchanged (Fig. 1).
Effects of gender and menstrual cycle on CFVR. Table 2
shows hemodynamic data, coronary flow velocity and
CFVR data in the study population. In premenopausal
women, no significant difference was seen in hemodynamics
between the M phase and F phase. No significant difference
in MDV at baseline was observed in premenopausal women
between the M and F phases. However, the two-way
ANOVA showed significant estrogen effect and interaction
in MDV over ATP (p  0.003 and p  0.0001, respec-
tively). In premenopausal women, MDV during ATP
infusion was significantly greater in the F phase compared
with that in the M phase (Table 2). Also, CFVR in the F
phase was greater than that in the M phase (Table 2, Fig. 2,
left). In men, CFVR remained unchanged (Table 2, Fig. 2,
right).
Effects of estradiol administration on CFVR. Hemody-
namic levels after CE intake did not differ from levels before
CE intake in postmenopausal women (Table 2). The MDV
at baseline was comparable in postmenopausal women
before and after administration of CE (Table 2). Two-way
Table 1. Clinical Characteristics of Subjects
Women Men
Premenopausal
Postmenopausal Initial
Follow-Up
at Two WeeksM Phase F Phase
Age (yr) 27  5 64  7 27  4
Hormone (pg/ml)
17-estradiol 25  9 123  9* 19  11 28  6 26  8
Lipids (mg/dl)
Total cholesterol 152  21 150  28 139  17 148  27 143  22
Triglycerides 70  36 51  17 63  14 66  11 66  8.0
HDL cholesterol 59  11 59  12 60  11 59  11 57  12
*p  0.0001 for the comparison with the value for the menstrual (M) phase.
F  follicular; HDL  high-density lipoprotein.
Figure 1. Individual change in serum 17-estradiol concentration in the menstrual (M) and follicular (F) phases in premenopausal women (left) and in
initial and second studies at two weeks in men (right).
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ANOVA showed significant interaction in MDV over ATP
(p  0.04). Also, CFVR significantly increased after CE
intake in postmenopausal women (Fig. 3, Table 2).
OBSERVER VARIABILITIES. Interobserver and intraobserver
variabilities for the measurement of Doppler velocity re-
cordings were 4.8% and 4.1%, respectively.
DISCUSSION
We have demonstrated that: 1) CFVR by TTDE varied
during the menstrual cycle depending on serum 17-
estradiol levels in premenopausal women, and 2) acute
estrogen replacement increased CFVR in postmenopausal
women.
The CFVR assessment by TTDE. Using TTDE, we
assessed CFVR, which has been alternatively used as coro-
nary flow reserve (8,9). Coronary flow reserve has been
reported to be reflective coronary microcirculation abnor-
mality in patients with hypercholesterolemia (10), diabetes
(11,12) and hypertension (13,14). In these studies, coronary
flow reserve was measured by positron emission tomogra-
phy, Doppler catheter or guide wire and transesophageal
Doppler echocardiography. Therefore, no coronary flow
reserve data of young subjects have been demonstrated prior
to this study. The TTDE we used in the present study is
completely noninvasive and a relatively inexpensive exami-
nation. Furthermore, this technique provides CFVR mea-
surement at a high success rate with a high-frequency
transducer and a reduced velocity range in color Doppler
echocardiography. Thus, this noninvasive technique was
suitable for evaluation of serial change in CFVR in the
present study subjects.
Effect of estrogen on coronary circulation. This is the
first report showing a relationship between CFVR and
estrogen level in young, healthy human subjects. We found
that CFVR varied depending on gender and on menstrual
cycle in female subjects and that the variation was associated
with the increase in serum 17-estradiol concentration
during the menstrual cycle. We also found that CFVR in
male subjects was comparable to that in premenopausal
women in the M phase and in postmenopausal women, and
that estrogen supplementation increased CFVR in post-
Table 2. Hemodynamics and Coronary Flow Velocity Measurements
Women Men
Premenopausal Postmenopausal
Initial
Follow-Up
at Two WeeksM Phase F Phase Before CE After CE
HR (beats/min)
Baseline 67  6 66  6 67  6 69  6 66  5 68  6
ATP infusion 72  6 71  5 72  7 72  6 73  6 74  6
Systolic BP (mm Hg)
Baseline 118  11 119  10 129  9 130  9 123  9 123  9
ATP infusion 114  11 114  10 124  8 123  8 117  9 116  10
Diastolic BP (mm Hg)
Baseline 69  8 69  9 74  7 75  8 65  9 68  8
ATP infusion 65  8 65  8 67  7 68  8 59  9 62  9
MDV (cm/s)
Baseline 23  5 23  4 25  6 24  6 24  5 24  4
ATP infusion 85  23 114  19† 82  21 102  28 89  16 89  13
CFVR 3.7  0.8 4.8  0.4† 3.4  0.8 4.1  0.8* 3.7  0.6 3.8  0.5
*p  0.0001 for the comparison with the value for Before CE. †p  0.0001 for the comparison with the value for the menstrual (M) phase.
ATP  adenosine triphosphate; BP  blood pressure; CE  conjugated estrogen; CFVR  coronary flow velocity reserve; F  follicular; HR  heart rate; MDV  mean
diastolic velocity.
Figure 2. Individual change in coronary flow velocity reserve (CFVR) in the menstrual (M) and follicular (F) phases in premenopausal women (left) and
in initial and second studies at two weeks in men (right).
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menopausal women. These results suggest that estrogen
may be associated with an increase in CFVR and that
estrogen may have a good effect on coronary microcircula-
tion.
Possible mechanism of cardioprotective effect of estro-
gen. Several mechanisms have been proposed to explain the
cardioprotective effect of estrogen on postmenopausal
women. Some studies have shown that lower risk of
coronary heart disease is attributable to the favorable effects
of estrogen on lipid and lipoprotein levels (15,16). Other
mechanisms of potential benefit include antioxidant effects.
Antioxidant effects of estrogen, inhibiting low-density li-
poprotein (LDL) oxidation (17), result in enhancing nitric
oxide (NO) availability (18–20). Oxidized LDL interferes
with receptor-mediated stimulation and signal transduction
in the release of NO (19,20).
In addition, estrogen has been shown to increase tran-
scription and activity of NO synthase in endothelial cell
culture studies (21). Stefano et al. (22) have shown that
physiologic doses of estrogen immediately stimulate NO
release from human endothelial cells through activation of a
cell-surface estrogen receptor that is coupled to increases in
intracellular calcium. This rapid action of estrogen might be
one mechanism of increase in CFVR after acute hormone
replacement in the present study. However, further inves-
tigations will be necessary to clarify precisely the mechanism
of estrogen’s effect on CFVR.
Study limitations. There are several limitations in the
present study. First, the study measured coronary flow
velocity change in epicardial coronary artery, not coronary
flow volume, although assessment of coronary flow reserve is
ideal for estimation of coronary microcirculation. However,
change in coronary flow velocity during drug-induced hy-
peremia has been alternatively used for assessment of
coronary flow reserve because coronary flow velocity corre-
lates well with coronary flow reserve (23). The CFVR in
LAD could be reflective of coronary microcirculation.
Second, long-term effect of estrogen on CFVR has not
been evaluated in postmenopausal women, although we
showed acute effect of estrogen on CFVR. Further studies
are necessary to evaluate the long-term effect of estrogen on
CFVR in postmenopausal women.
A combination of estrogen and progesterone is more
frequently used owing to the risk of uterine cancer with
unopposed estrogen therapy. However, a randomized trial
showed that treatment with combined hormone replace-
ment therapy did not reduce the rate of coronary heart
disease events in postmenopausal women with established
coronary disease (24). It was also reported that combined
hormone replacement therapy in postmenopausal women
did not improve brachial artery flow-mediated vasodilation
(25). Further examination is needed to evaluate the effect of
combined hormone replacement therapy on coronary circu-
lation in healthy postmenopausal women.
Conclusions. We draw the following conclusions from this
study: 1) in premenopausal women, CFVR determined by
TTDE varied during the menstrual cycle depending on
serum 17-estradiol level; and 2) the CFVR increased after
acute estrogen replacement in postmenopausal women.
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